Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Active Pharmaceutical Ingredients CDMO Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Molecule Type (Small Molecule, Large Molecule)
5.2.2. By Synthesis (Biotech, Synthetic)
5.2.3. By Drug Type (Innovative, Generics)
5.2.4. By Workflow (Clinical, Commercial)
5.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.7. By Company (2023)
5.3. Market Map
5.3.1 By Molecule Type
5.3.2 By Synthesis
5.3.3 By Drug Type
5.3.4 By Workflow
5.3.5 By Application
5.3.6 By Region

6. North America Active Pharmaceutical Ingredients CDMO Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Molecule Type (Small Molecule, Large Molecule)
6.2.2. By Synthesis (Biotech, Synthetic)
6.2.3. By Drug Type (Innovative, Generics)
6.2.4. By Workflow (Clinical, Commercial)
6.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Molecule Type
6.3.1.2.2. By Synthesis
6.3.1.2.3. By Drug Type
6.3.1.2.4. By Workflow
6.3.1.2.5. By Application
6.3.2. Canada Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Molecule Type
6.3.2.2.2. By Synthesis
6.3.2.2.3. By Drug Type
6.3.2.2.4. By Workflow
6.3.2.2.5. By Application
6.3.3. Mexico Active Pharmaceutical Ingredients CDMO Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Molecule Type
6.3.3.2.2. By Synthesis
6.3.3.2.3. By Drug Type
6.3.3.2.4. By Workflow
6.3.3.2.5. By Application

7. Europe Active Pharmaceutical Ingredients CDMO Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Molecule Type (Small Molecule, Large Molecule)
7.2.2. By Synthesis (Biotech, Synthetic)
7.2.3. By Drug Type (Innovative, Generics)
7.2.4. By Workflow (Clinical, Commercial)
7.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. France Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Molecule Type
7.3.1.2.2. By Synthesis
7.3.1.2.3. By Drug Type
7.3.1.2.4. By Workflow
7.3.1.2.5. By Application
7.3.2. Germany Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Molecule Type
7.3.2.2.2. By Synthesis
7.3.2.2.3. By Drug Type
7.3.2.2.4. By Workflow
7.3.2.2.5. By Application
7.3.3. United Kingdom Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Molecule Type
7.3.3.2.2. By Synthesis
7.3.3.2.3. By Drug Type
7.3.3.2.4. By Workflow
7.3.3.2.5. By Application
7.3.4. Italy Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Molecule Type
7.3.4.2.2. By Synthesis
7.3.4.2.3. By Drug Type
7.3.4.2.4. By Workflow
7.3.4.2.5. By Application
7.3.5. Spain Active Pharmaceutical Ingredients CDMO Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Molecule Type
7.3.5.2.2. By Synthesis
7.3.5.2.3. By Drug Type
7.3.5.2.4. By Workflow
7.3.5.2.5. By Application

8. Asia-Pacific Active Pharmaceutical Ingredients CDMO Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Molecule Type (Small Molecule, Large Molecule)
8.2.2. By Synthesis (Biotech, Synthetic)
8.2.3. By Drug Type (Innovative, Generics)
8.2.4. By Workflow (Clinical, Commercial)
8.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Molecule Type
8.3.1.2.2. By Synthesis
8.3.1.2.3. By Drug Type
8.3.1.2.4. By Workflow
8.3.1.2.5. By Application
8.3.2. India Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Molecule Type
8.3.2.2.2. By Synthesis
8.3.2.2.3. By Drug Type
8.3.2.2.4. By Workflow
8.3.2.2.5. By Application
8.3.3. Japan Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Molecule Type
8.3.3.2.2. By Synthesis
8.3.3.2.3. By Drug Type
8.3.3.2.4. By Workflow
8.3.3.2.5. By Application
8.3.4. South Korea Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Molecule Type
8.3.4.2.2. By Synthesis
8.3.4.2.3. By Drug Type
8.3.4.2.4. By Workflow
8.3.4.2.5. By Application
8.3.5. Australia Active Pharmaceutical Ingredients CDMO Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Molecule Type
8.3.5.2.2. By Synthesis
8.3.5.2.3. By Drug Type
8.3.5.2.4. By Workflow
8.3.5.2.5. By Application
9. South America Active Pharmaceutical Ingredients CDMO Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Molecule Type (Small Molecule, Large Molecule)
9.2.2. By Synthesis (Biotech, Synthetic)
9.2.3. By Drug Type (Innovative, Generics)
9.2.4. By Workflow (Clinical, Commercial)
9.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Molecule Type
9.3.1.2.2. By Synthesis
9.3.1.2.3. By Drug Type
9.3.1.2.4. By Workflow
9.3.1.2.5. By Application
9.3.2. Argentina Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Molecule Type
9.3.2.2.2. By Synthesis
9.3.2.2.3. By Drug Type
9.3.2.2.4. By Workflow
9.3.2.2.5. By Application
9.3.3. Colombia Active Pharmaceutical Ingredients CDMO Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Molecule Type
9.3.3.2.2. By Synthesis
9.3.3.2.3. By Drug Type
9.3.3.2.4. By Workflow
9.3.3.2.5. By Application

10. Middle East and Africa Active Pharmaceutical Ingredients CDMO Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Molecule Type (Small Molecule, Large Molecule)
10.2.2. By Synthesis (Biotech, Synthetic)
10.2.3. By Drug Type (Innovative, Generics)
10.2.4. By Workflow (Clinical, Commercial)
10.2.5. By Application (Cardiology, Oncology, Ophthalmology, Neurology, Orthopedic, Other)
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Molecule Type
10.3.1.2.2. By Synthesis
10.3.1.2.3. By Drug Type
10.3.1.2.4. By Workflow
10.3.1.2.5. By Application
10.3.2. Saudi Arabia Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Molecule Type
10.3.2.2.2. By Synthesis
10.3.2.2.3. By Drug Type
10.3.2.2.4. By Workflow
10.3.2.2.5. By Application
10.3.3. UAE Active Pharmaceutical Ingredients CDMO Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Molecule Type
10.3.3.2.2. By Synthesis
10.3.3.2.3. By Drug Type
10.3.3.2.4. By Workflow
10.3.3.2.5. By Application

11. Market Dynamics
11.1. Drivers
11.2. Challenges

12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Active Pharmaceutical Ingredients CDMO Market: SWOT Analysis

14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape
15.1. Cambrex Corporation
15.1.1. Business Overview
15.1.2. Product Offerings
15.1.3. Recent Developments
15.1.4. Financials (As Reported)
15.1.5. Key Personnel
15.1.6. SWOT Analysis
15.2. Patheon (Thermo Fisher Scientific Inc.)
15.2.1. Business Overview
15.2.2. Product Offerings
15.2.3. Recent Developments
15.2.4. Financials (As Reported)
15.2.5. Key Personnel
15.2.6. SWOT Analysis
15.3. Recipharm AB
15.3.1. Business Overview
15.3.2. Product Offerings
15.3.3. Recent Developments
15.3.4. Financials (As Reported)
15.3.5. Key Personnel
15.3.6. SWOT Analysis
15.4. CordenPharma International
15.4.1. Business Overview
15.4.2. Product Offerings
15.4.3. Recent Developments
15.4.4. Financials (As Reported)
15.4.5. Key Personnel
15.4.6. SWOT Analysis
15.5. Samsung Biologics
15.5.1. Business Overview
15.5.2. Product Offerings
15.5.3. Recent Developments
15.5.4. Financials (As Reported)
15.5.5. Key Personnel
15.5.6. SWOT Analysis
15.6. Lonza Group
15.6.1. Business Overview
15.6.2. Product Offerings
15.6.3. Recent Developments
15.6.4. Financials (As Reported)
15.6.5. Key Personnel
15.6.6. SWOT Analysis
15.7. Siegfried
15.7.1. Business Overview
15.7.2. Product Offerings
15.7.3. Recent Developments
15.7.4. Financials (As Reported)
15.7.5. Key Personnel
15.7.6. SWOT Analysis
15.8. Piramal Pharma Solutions
15.8.1. Business Overview
15.8.2. Product Offerings
15.8.3. Recent Developments
15.8.4. Financials (As Reported)
15.8.5. Key Personnel
15.8.6. SWOT Analysis
15.9. AbbVie Inc.
15.9.1. Business Overview
15.9.2. Product Offerings
15.9.3. Recent Developments
15.9.4. Financials (As Reported)
15.9.5. Key Personnel
15.9.6. SWOT Analysis
15.10. Catalent Inc.
15.10.1. Business Overview
15.10.2. Product Offerings
15.10.3. Recent Developments
15.10.4. Financials (As Reported)
15.10.5. Key Personnel
15.10.6. SWOT Analysis

16. Strategic Recommendations